Study guide
2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus)
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus)
Key Takeaways Explain This Topic AI
Genital herpes is diagnosed definitively via viral PCR of active lesions; oral antiviral suppression with acyclovir or valacyclovir is initiated at 36 weeks gestation to reduce viral shedding and prevent cesarean delivery.
Condyloma acuminata are caused by low-risk HPV types 6 and 11; provider-administered cryotherapy or trichloroacetic acid (TCA) are safe in pregnancy, whereas podofilox and sinecatechins should not be used and imiquimod should be avoided.
Lichen sclerosus presents with porcelain-white crinkled plaques, architectural fusion, and intractable pruritus that spares the vagina; confirmation via punch biopsy is required due to a 4-5% risk of squamous cell carcinoma.
First-line therapy for lichen sclerosus consists of an ultra-potent topical corticosteroid (clobetasol propionate 0.05% ointment) taper, whereas erosive lichen planus frequently involves the vaginal canal causing desquamative vaginitis.
Acute Bartholin abscess is treated with incision and drainage with Word catheter placement for 4 to 6 weeks; any new or enlarging Bartholin mass in a woman older than 40 years mandates biopsy to exclude Bartholin adenocarcinoma.
Last updated: October 2026
Viral STIs & Chronic Vulvar Dermatoses
Evaluating vulvar pathology requires distinguishing infectious ulcerative and verrucous entities from chronic inflammatory dermatoses and glandular disorders. While these conditions often share symptoms of pruritus, burning, and dyspareunia, their etiologies, malignant potentials, and therapeutic regimens differ profoundly. Women's Health Nurse Practitioners must master point-of-care differentiation, biopsy indications, and evidence-based pharmacotherapy for viral STIs, chronic dermatoses, and vestibular conditions.
Important
Any persistent, uncharacterized vulvar lesion, plaque, or architectural alteration unresponsive to initial therapy requires a 3 to 4 mm Keyes punch biopsy to establish histological diagnosis and exclude differentiated vulvar intraepithelial neoplasia (dVIN) or squamous cell carcinoma.
Herpes Simplex Virus (HSV-1 & HSV-2)
Genital herpes is a lifelong viral infection caused by HSV-1 or HSV-2. Following mucosal inoculation, the virus ascends sensory peripheral nerves to establish latency within lumbosacral dorsal root ganglia (S2–S4).
Clinical Manifestations
Primary Episode: Severe systemic symptoms (fever, malaise, tender bilateral inguinal lymphadenopathy) and extensive, exquisitely painful bilateral vesicles that ulcerate and crust over 2 to 3 weeks. Dysuria and urinary retention are common.
Recurrent Outbreaks: Milder, unilateral, and self-limiting (healing in 5–10 days), typically preceded by a sensory prodrome (tingling, burning paresthesias in the perineum or buttocks 12–24 hours prior).
Diagnostics & Pharmacotherapy
Diagnostics: Viral swab of an unroofed vesicular base for HSV Polymerase Chain Reaction (PCR) is the gold standard, offering superior sensitivity over viral culture. Type-specific glycoprotein G serology differentiates HSV-1 from HSV-2 when lesions are absent.
Primary Outbreak: Oral valacyclovir 1 g twice daily for 7–10 days, or oral acyclovir 400 mg three times daily for 7–10 days.
Episodic Therapy: Initiated during prodrome or within 24 hours of onset (valacyclovir 500 mg twice daily for 3 days or famciclovir).
Daily Suppressive Therapy: Recommended for frequent recurrences (>=6 episodes per year) or to reduce partner transmission (valacyclovir 500 mg or 1,000 mg daily).
Antepartum Management: Daily oral suppressive therapy (acyclovir 400 mg three times daily or valacyclovir 500 mg twice daily) is initiated at 36 weeks of gestation until delivery for women with genital herpes. This suppresses viral shedding and recurrences at term, avoiding cesarean delivery. If active lesions or prodrome exist at labor, cesarean delivery is mandatory.
Human Papillomavirus (HPV) & Condyloma Acuminata
Condyloma acuminata (anogenital warts) are benign proliferative lesions caused predominantly by non-oncogenic low-risk HPV types 6 and 11 (>90% of cases), whereas high-risk oncogenic types (HPV 16, 18, 31, 33, 45) cause intraepithelial neoplasia and cervical/vulvar carcinomas.
Clinical Presentation & Treatments
Warts appear as flesh-colored, exophytic, verrucous, cauliflower-like, sessile, or pedunculated papules.
Patient-Applied (Home):
Imiquimod 5% cream: Applied at bedtime 3 times weekly for up to 16 weeks; washed off after 6–10 hours. Immune response modifier. (Avoid in pregnancy; CDC notes low apparent risk but insufficient data.)
Podofilox 0.5% solution/gel: Applied twice daily for 3 consecutive days, then 4 days off, up to 4 cycles. Antimitotic. (Contraindicated in pregnancy).
Provider-Applied (Clinical):
Liquid Nitrogen Cryotherapy: Applied until lesions freeze with a 1–2 mm halo, repeated every 1–2 weeks. Safe in pregnancy.
Trichloroacetic Acid (TCA) 80–90%: Applied chemically until white frosting occurs. Safe in pregnancy.
Chronic Vulvar Dermatoses
Clinical Feature Lichen Sclerosus (LS) Lichen Planus (LP)
Pathophysiology Autoimmune chronic dermal collagen sclerosis T-cell-mediated autoimmune mucocutaneous dermatosis
- Key Symptoms Severe, intractable pruritus (worse at night) Pain, burning, severe dyspareunia, pruritus
- Appearance Ivory-white, parchment-like, crinkled plaques Shiny erythematous erosions, Wickham striae
- Architecture Resorption of labia minora, clitoral phimosis Synechiae, vaginal adhesions, introital stenosis
- Distribution "Figure-of-eight" perianal halo; spares vagina Vulva, oral mucosa, and frequently involves vagina
- Malignant Risk 4–5% lifetime risk of squamous cell carcinoma (SCC) Low risk of squamous cell carcinoma (<2–3%)
First-Line Therapy Ultra-potent topical steroid (Clobetasol 0.05% taper) Ultra-potent topical steroid; intravaginal hydrocortisone
Lichen Sclerosus (LS)
LS is a chronic inflammatory dermatosis common in postmenopausal women, characterized by porcelain-white plaques with a wrinkled "cigarette paper" texture and a "figure-of-eight" perianal distribution. Severe architectural loss occurs: labia minora resorb, the clitoral prepuce fuses (phimosis), and the introitus constricts. The vaginal mucosa is never involved . Diagnosis requires a 3 to 4 mm Keyes punch biopsy. First-line therapy is an ultra-potent topical corticosteroid (clobetasol propionate 0.05% ointment) applied nightly for 4 weeks, alternate nights for 4 weeks, then twice weekly for maintenance, with lifetime surveillance.
Lichen Planus (LP)
Lichen planus presents as erosive, papular, or hypertrophic forms. Unlike lichen sclerosus, erosive lichen planus regularly affects the vagina , causing desquamative inflammatory vaginitis, friability, serosanguinous discharge, and synechiae that obliterate vaginal fornices. Oral Wickham striae (lacy white streaks) are common. Management requires topical clobetasol 0.05% ointment for vulvar lesions and intravaginal hydrocortisone suppositories (25 mg BID) for vaginal disease.
Bartholin Gland Cyst and Abscess
The paired Bartholin glands lie at the 4 and 8 o'clock positions of the posterolateral vestibule. Duct obstruction produces a painless retention cyst; secondary polymicrobial superinfection generates an acute Bartholin abscess—an exquisitely tender, fluctuant labial mass.
Clinical Management
Incision & Drainage with Word Catheter: Simple I&D without catheterization yields recurrence in >50% of cases. Clinicians perform incision and insert a Word catheter, inflating the balloon with 2 to 3 mL of sterile saline for 4 to 6 weeks to ensure epithelialization of a permanent tract. Marsupialization is reserved for recurrent cysts.
Biopsy in Women Over 40: Any newly developing or persistent Bartholin mass in a woman older than 40 years requires biopsy of the cyst wall to rule out Bartholin gland adenocarcinoma , a rare but aggressive malignancy.